Abstract 1671P
Background
The rise of the internet has transformed communication and healthcare, allowing easy access to sensitive medical test results. However, this practice lacks regulation. Breast cancer, the most common cancer in women, has seen improved survival rates, leading to more individuals living with the disease. Patients accessing their results online can pose challenges for oncologists due to the anxiety stemming from this constant access. Studies show conflicting outcomes regarding the emotional impact of this access, ranging from increased patient engagement to heightened anxiety. This study aims to investigate whether online receipt of sensitive results can worsen the emotional health of oncology patients, for instance, by intensifying anxiety symptoms.
Methods
This cross-sectional study employed a questionnaire with four sections to assess patients diagnosed with breast cancer within five years. The questionnaire covered demographic information, online test result access habits, anxiety levels during result anticipation, and validated screening tools for personality disorders (PID-5-BF), anxiety (GAD-7), and depression (PHQ-9). Sample size estimation for confidence interval calculations targeted 385 patients. The current analysis includes data from 198 respondents.
Results
Among the 198 participants, 196 (99%) were female, with only 2 (1%) being male. The majority (75.3%) received their breast cancer diagnosis within the past 1 to 5 years. In terms of cancer staging, 41.4% had early-stage disease (Stages I-III), while 57.6% had advanced-stage disease (Stage IV). Concerning online result access, 25.3% reported infrequent online result checks, while 74.2% confirmed habitual checking. During result anticipation, 64.6% expressed anxiety, primarily described as mild (62.2%). Statistical analyses indicated no significant association between online result access behavior and anxiety levels (p=0.609), anxiety disorders (p=0.411), or depressive disorders (p=0.484).
Conclusions
This interim analysis did not reveal a correlation between receiving potentially sensitive test results online and patient anxiety. Recruitment is ongoing and on target to produce a final analysis in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11